Taigo Kato

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6549752/publications.pdf

Version: 2024-02-01

56 papers	1,308 citations	331670 21 h-index	395702 33 g-index
58 all docs	58 docs citations	58 times ranked	1933 citing authors

#	Article	IF	Citations
1	A case of perirenal nonâ€specific lymphadenitis mimicking a solitary renal mass. IJU Case Reports, 2022, 5, 10-13.	0.3	1
2	Editorial Comment from Dr. Kato to Recurrent urinary retention due to clots caused by a congenital renal arteriovenous malformation that forms a complex vascular network: Report of two cases. IJU Case Reports, 2022, 5, 8-9.	0.3	0
3	Everolimus Reduces Cancer Incidence and Improves Patient and Graft Survival Rates after Kidney Transplantation: A Multi-Center Study. Journal of Clinical Medicine, 2022, 11, 249.	2.4	3
4	CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	68
5	Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma. International Journal of Urology, 2022, 29, 462-469.	1.0	6
6	Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma. Cancer Science, 2022, 113, 1830-1842.	3.9	11
7	Incidence and mortality of postâ€transplant lymphoproliferative disorders after kidney transplantation: A realâ€world retrospective analysis in Japan. International Journal of Urology, 2022, 29, 206-211.	1.0	1
8	Highâ€fat diet promotes prostate cancer growth through histamine signaling. International Journal of Cancer, 2022, 151, 623-636.	5.1	12
9	Editorial Comment to Determining programmed cell death ligand 1 expression in circulating tumor cells of patients with clear cell renal cell carcinoma and its correlation with response to programmed cell death protein 1 inhibitors. International Journal of Urology, 2022, 29, 954-955.	1.0	0
10	Trop-2 in Upper Tract Urothelial Carcinoma. Current Oncology, 2022, 29, 3911-3921.	2.2	13
11	Circulating extracellular vesicles carrying Firmicutes reflective of the local immune status may predict clinical response to pembrolizumab in urothelial carcinoma patients. Cancer Immunology, Immunotherapy, 2022, 71, 2999-3011.	4.2	4
12	Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study. International Journal of Clinical Oncology, 2022, 27, 1596-1604.	2.2	11
13	Cumulative cancer incidence and mortality after kidney transplantation in Japan: A longâ€term multicenter cohort study. Cancer Medicine, 2021, 10, 2205-2215.	2.8	15
14	Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using lowâ€dose methylprednisolone. IJU Case Reports, 2021, 4, 22-24.	0.3	6
15	Fragmentation of cellâ€free DNA is induced by upperâ€tract urothelial carcinomaâ€“associated systemic inflammation. Cancer Science, 2021, 112, 168-177.	3.9	6
16	Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma. OncoImmunology, 2021, 10, 1862948.	4.6	20
17	Therapeutic and Clinical Outcomes of Robot-assisted Partial NephrectomyVersusCryoablation for T1 Renal Cell Carcinoma. In Vivo, 2021, 35, 1573-1579.	1.3	9
18	Proteomic analysis of urinary and tissueâ€exudative extracellular vesicles to discover novel bladder cancer biomarkers. Cancer Science, 2021, 112, 2033-2045.	3.9	35

#	Article	IF	Citations
19	Durable response of chemotherapy for cancer of unknown primary with unfavorable subset developed in retroperitoneal space. IJU Case Reports, 2021, 4, 255-258.	0.3	0
20	Gut Microbiotaâ€“Derived Short-Chain Fatty Acids Promote Prostate Cancer Growth via IGF1 Signaling. Cancer Research, 2021, 81, 4014-4026.	0.9	83
21	The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study. International Journal of Clinical Oncology, 2021, 26, 954-961.	2.2	9
22	Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma. Anticancer Research, 2021, 41, 5811-5816.	1.1	4
23	Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma. International Journal of Molecular Sciences, 2020, 21, 5390.	4.1	48
24	A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma. Anticancer Research, 2020, 40, 4875-4883.	1.1	6
25	Resumption of antiâ€programmed cell death 1 monotherapy for severe immuneâ€related adverse events experienced patient with renal cell carcinoma. IJU Case Reports, 2020, 3, 176-179.	0.3	1
26	Efficacy of a Si-based agent against developing renal failure in a rat remnant kidney model. Biochemical and Biophysical Research Communications, 2020, 533, 698-703.	2.1	4
27	Clinical Efficacy of Intravenous Immunoglobulin for BK Polyomavirus-Associated Nephropathy After Living Kidney Transplantation . Therapeutics and Clinical Risk Management, 2020, Volume 16, 947-952.	2.0	11
28	Intratumoral and s.c. injection of inactivated hemagglutinating virus of Japan envelope (GEN0101) in metastatic castrationâ€resistant prostate cancer. Cancer Science, 2020, 111, 1692-1698.	3.9	12
29	MicroRNAâ€92bâ€3p is a prognostic oncomiR that targets TSC1 in clear cell renal cell carcinoma. Cancer Science, 2020, 111, 1146-1155.	3.9	19
30	The role of actinin-4 (ACTN4) in exosomes as a potential novel therapeutic target in castration-resistant prostate cancer. Biochemical and Biophysical Research Communications, 2020, 523, 588-594.	2.1	28
31	Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma. International Immunology, 2020, 32, 347-357.	4.0	10
32	Oral Administration of Si-Based Agent Attenuates Oxidative Stress and Ischemia-Reperfusion Injury in a Rat Model: A Novel Hydrogen Administration Method. Frontiers in Medicine, 2020, 7, 95.	2.6	15
33	Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma. Scientific Reports, 2020, 10, 6220.	3.3	25
34	Leukocyteâ€‘associated immunoglobulinâ€‘like receptorï¿½1 promotes tumorigenesis in RCC. Oncology Reports, 2019, 41, 1293-1303.	2.6	16
35	Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma. International Journal of Clinical Oncology, 2019, 24, 78-86.	2.2	3
36	Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma. Cancer Science, 2019, 110, 617-628.	3.9	61

#	Article	IF	Citations
37	TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients. OncoImmunology, 2019, 8, e1588085.	4.6	17
38	Diagnostic potential of <scp>TERT</scp> promoter and <scp>FGFR</scp>3 mutations in urinary cellâ€free <scp>DNA</scp> in upper tract urothelial carcinoma. Cancer Science, 2019, 110, 1771-1779.	3.9	63
39	Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma. OncoImmunology, 2019, 8, e1568813.	4.6	31
40	Phenotypic Analysis of Tumor Tissueâ€“Infiltrating Lymphocytes in Tumor Microenvironment of Bladder Cancer and Upper Urinary Tract Carcinoma. Clinical Genitourinary Cancer, 2019, 17, 114-124.	1.9	8
41	Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptorâ€“Engineered T Cells for Ovarian Cancer. Clinical Cancer Research, 2018, 24, 5357-5367.	7.0	70
42	Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells. Oncotarget, 2018, 9, 11009-11019.	1.8	44
43	The era of immunogenomics/immunopharmacogenomics. Journal of Human Genetics, 2018, 63, 865-875.	2.3	15
44	Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of in vitro expanded populations in head and neck cancer. Oncotarget, 2018, 9, 3805-3814.	1.8	6
45	A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. Oncotarget, 2018, 9, 18985-18996.	1.8	83
46	Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma. Oncotarget, 2018, 9, 20467-20475.	1.8	38
47	Characterization of the cryoablation-induced immune response in kidney cancer patients. OncoImmunology, 2017, 6, e1326441.	4.6	34
48	<scp>TOPK</scp> (Tâ€<scp>LAK</scp> cellâ€originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer. Cancer Science, 2017, 108, 488-496.	3.9	28
49	p53-independent p21 induction by MELK inhibition. Oncotarget, 2017, 8, 57938-57947.	1.8	35
50	Integrated analysis of somatic mutations and immune microenvironment of multiple regions in breast cancers. Oncotarget, 2017, 8, 62029-62038.	1.8	28
51	Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown. Neoplasia, 2016, 18, 265-272.	5.3	27
52	The benefits of cancer screening in kidney transplant recipients: a singleâ€center experience. Cancer Medicine, 2016, 5, 153-158.	2.8	18
53	T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer. Clinical Cancer Research, 2016, 22, 6110-6117.	7.0	63
54	Germline PARP4 mutations in patients with primary thyroid and breast cancers. Endocrine-Related Cancer, 2016, 23, 171-179.	3.1	39

#	Article	IF	Citations
55	Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. Oncotarget, 2016, 7, 13621-13633.	1.8	41
56	Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells. Oncotarget, 2016, 7, 17652-17664.	1.8	44